key: cord-0773894-tcxrp52z
authors: Selvaraj, Senthil; Greene, Stephen J.; Khatana, Sameed Ahmed M.; Nathan, Ashwin S.; Solomon, Scott D.; Bhatt, Deepak L.
title: The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID‐19
date: 2020-09-09
journal: J Am Heart Assoc
DOI: 10.1161/jaha.120.018274
sha: 484c1091c9e931c86e7af6e16ea6213c8a6c4e5a
doc_id: 773894
cord_uid: tcxrp52z

The Coronavirus Disease 2019 (COVID-19) pandemic has taken an unprecedented toll on the American healthcare system and economy. While numerous COVID-19 clinical trials have been initiated in hopes of curtailing its impact, most pre-existing clinical trials have been forced to suspend or limit activity, which itself can have significant consequences. Missed or postponed trial-related assessments may hinder data quality, and heterogeneity in data collection both across the country and over time introduces bias. In addition, COVID-19 may lower specific event rates due to patients avoiding the healthcare system that could result in underpowered outcome analyses, or conversely, some endpoints (mortality) may be inflated.

T he coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented toll on the American healthcare system and economy. While numerous COVID-19 clinical trials have been initiated in hopes of curtailing its impact, most preexisting clinical trials have been forced to suspend or limit activity, which itself can have significant consequences. Missed or postponed trial-related assessments may hinder data quality, and heterogeneity in data collection both across the country and over time introduces bias. 1 In addition, COVID-19 may lower specific event rates due to patients avoiding the healthcare system that could result in underpowered outcome analyses, or conversely, some end points (mortality) may be inflated. 2 Nonetheless, while the pandemic has exerted a significant toll on preexisting clinical trials, the increasingly recognized interplay of COVID-19 with the cardiovascular system has prompted an urgent need for new studies. 3 As such, clinical trials have rapidly commenced to study the impact of COVID-19 on cardiovascular populations and outcomes, as well as to test the effects of cardiovascular therapies on COVID-19 disease course (eg, inhibitors of the renin-angiotensin-aldosterone system). 4 However, to date, the impact of COVID-19 on the landscape and scope of preexisting and newly initiated cardiovascular clinical trials has not been systematically studied.

We extracted data from clini caltr ials.gov to describe characteristics of (1) cardiovascular clinical trials before COVID-19 and (2) COVID-19 trials with a cardiovascular focus in the United States as of May 13, 2020. All trials were required to be recruiting, enrolling by invitation, active but not recruiting, or suspended. Two reviewers classified all data not populated by the trials database. To define pre-COVID-19 cardiovascular clinical trials, we used the preferred search term "cardiac disease" (which simultaneously searches synonyms), initially identifying 905 trials. We then excluded trials with a start date after March 16, 2020, when national guidance for social distancing was issued (final n=892). COVID-19 trials were similarly identified by the preferred search term "COVID-19." From these COVID-19 trials (n=156), we defined cardiovascular COVID-19 trials by any of the following: a specific cardiovascular patient population (ie, patients with heart failure), a cardiovascular intervention (ie, primary cardiac drug therapy), or cardiovascular outcome (ie, cardiac events or biomarkers) (final n=25). Corresponding coronavirus case load on May 13, 2020, per state was downloaded. 5 Our investigation did not require institutional review board approval because all data were acquired from the public domain.

Among 892 pre-COVID-19 cardiovascular trials (Table) , the most common trial topics are heart failure (29%), electrophysiology (25%), and interventional cardiology (18%). Approximately half (54%) receive industry or federal funding, and trial phases are roughly evenly distributed. Most pre-COVID-19 trials occur in states with a substantial COVID-19 case load (New York, California, and Pennsylvania). The median (25th-75th (Table) , 7 (28%) specifically enroll a cardiovascular population, and 13 (52)% employ a cardiovascular intervention (with renin-angiotensin-aldosterone system-based interventions occurring in 6 [24%]). Sixteen trials (64%) assess a cardiovascular outcome, and 8 (32%) specifically study a biomarker outcome (7 prespecified troponin and 5 prespecified natriuretic peptides). The most frequent trial sites are located in New York, California, and North Carolina. Fourteen studies are in phase II, and 4 receive industry or federal funding. The median (25th-75th percentile) time until anticipated trial completion is 232 (180-323) days.

Here, we describe the characteristics of active cardiovascular clinical trials initiated before COVID-19 as well as recently initiated COVID-19 trials with a cardiovascular focus. Of the 892 pre-COVID-19 clinical trials, many enroll in states with substantial COVID-19 burden that are likely suspended or limited in activity. Further, more than a quarter were anticipated to complete within 6 months. Heart failure, electrophysiology, and interventional cardiology trials are the most frequent ongoing trials. In the COVID-19 era, a modest number of studies (25) include a cardiovascular patient population, intervention, or outcome. These trials, mostly in phase II, reflect the substantial interest in renin-angiotensin-aldosterone system-based therapies, principally use biomarker outcomes, and are largely anticipated to report in 2021. 3, 4 While systematically searched, our data are limited to documented fields, and are thus predicated on accurately entered and updated information. In addition, these data will continue to evolve as further research is stimulated during the pandemic.

In conclusion, we present the landscape of ongoing cardiovascular clinical trials that were initiated before COVID-19, as well as the characteristics of recently initiated COVID-19 clinical trials with a cardiovascular focus. Such data underscore the magnitude of the toll COVID-19 has taken on the clinical trial community and provide insight into new directions of cardiac-focused COVID-19 research.

The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials

Reduction in st-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Potential effects of coronaviruses on the cardiovascular system: a review

Renin-angiotensin-aldosterone system inhibitors in patients with covid-19

s-us-cases.html?actio n=click &pgtyp e=Artic le&state =defau lt&-modul e=styln -coron aviru s&varia nt=show&regio n=TOP_BANNE R&conte xt=story lines_menu#states

None.

Dr Selvaraj receives research support from the National Institutes of Health (Training Grant 5-T32HL007843-